We also selected SP100 to test its potential as a marker of low risk, since we previously found it to reposition in a low risk Gleason score 6 prostate cancer, but not in three intermediate or high-risk Gleason score 7 cancers (Leshner et al., 2016). Here, SP100 is linked to prostate carcinoma.